74,14 <%= Resources.Global.txtUp %>
Opdateret 12:41:25
Ændring % 1,70% Stigning i aktiekurs
Ændring 1,24 Stigning i aktiekurs
Volume 121.821
Høj 74,44
Lav 72,74
Åben 73,00
ISIN BE0003739530
Seneste luk 72,90
# af aktier 194,51M
Markedsværdi 14.421M EUR
I dag

UCB
Markedet er åbent (indtil 17:30) - Forsinket 15 min
 
Kursudvikling Seneste 1 uge 1 måned 3 mdr 6 mdr 1 år
 
  74,14 0,4% Stigning i aktiekurs -4,8% Fald i aktiekurs 5,0% Stigning i aktiekurs 13,6% Stigning i aktiekurs 20,6% Stigning i aktiekurs
Powered by TradingView

Firmaprofil

UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, both of which have lost patent protection. The firm's newer key drugs include Cimzia (rheumatoid arthritis, psoriatic arthritis, and Crohn's disease), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), and Briviact (epilepsy).

Copyright Berlingske Media 2018  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
22. oktober 2018 12:56:56
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20181021.1 - EUROWEB6 - 2018-10-22 12:56:56 - 2018-10-22 12:56:56 - 1 - Website: OKAY